Questo sito utilizza cookie, propri e di altri siti, solo al fine di garantire una navigazione ottimale e di raccogliere statistiche anonime sui dati di navigazione senza alcuna profilazione dell’utente.

Se vuoi saperne di più o negare il consenso a tutti o ad alcuni cookie clicca qui.

Se accedi a un qualunque elemento sottostante questo banner acconsenti automaticamente all’uso dei cookie.

Accetto

  1. Galileo Research »
  2. Opportunità per Investitori »
  3. Partnering

Partnering

Galileo Research is seeking a partner to raise funding for Phase II and Phase III development for TALL-104 program in ovarian cancer. Ovarian cancer is the second most common gynecological malignancy among women. Among the seven major markets, it has affected around 170,000 women in 2010, with the UK having the highest prevalence among the top five EU countries. The prevalence of ovarian cancer is set to grow from 170,280 in 2010 to 174,429 in 2016. Approximately 70% of the patients with ovarian cancer are diagnosed with advanced disease. The standard treatment includes surgery, followed by a combination of platinum and taxane adjuvant chemotherapy.